# Adaptive metrics for an evolving pandemic A dynamic approach to area-level COVID-19 risk designations

Alyssa M. Bilinski<sup>a,1</sup>, Joshua A. Salomon<sup>b</sup>, and Laura A. Hatfield<sup>c</sup>

<sup>a</sup> Departments of Health Services, Policy and Practice & Biostatistics, Brown University, 121 S. Main St., Providence, RI 02912 USA; <sup>b</sup>Department of Health Policy, Stanford University, Stanford, CA 94305 USA; <sup>c</sup>Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave., Boston, MA 02115 USA

Throughout the COVID-19 pandemic, policymakers have proposed risk metrics, such as the CDC Community Levels, to guide local and state 2 decision-making. However, risk metrics have not reliably predicted 3 key outcomes and often lack transparency in terms of prioritization of false positive versus false negative signals. They have also struggled 5 to maintain relevance over time due to slow and infrequent updates 6 addressing new variants and shifts in vaccine- and infection-induced 7 immunity. We make two contributions to address these weaknesses 8 of risk metrics. We first present a framework to evaluate predictive accuracy based on policy targets related to severe disease and mor-10 tality, allowing for explicit preferences toward false negative versus 11 false positive signals. This approach allows policymakers to opti-12 mize metrics for specific preferences and interventions. Second, we 13 propose a novel method to update risk thresholds in real-time. We 14 show that this adaptive approach to designating areas as "high risk" 15 improves performance over static metrics in predicting 3-week-ahead 16 17 mortality and intensive care usage at both state and county levels. We also demonstrate that with our approach, using only new hospital ad-18 missions to predict 3-week-ahead mortality and intensive care usage 19 has performed consistently as well as metrics that also include cases 20 and inpatient bed usage. Our results highlight that a key challenge 21 for COVID-19 risk prediction is the changing relationship between in-22 23 dicators and outcomes of policy interest. Adaptive metrics therefore 24 have a unique advantage in a rapidly evolving pandemic context.

Infectious disease dynamics | Decision theory | Risk prediction | COVID-19

nderstanding the evolution of infectious disease risk 1 is critical for individuals making decisions about per-2 sonal precautions, policymakers recommending mitigation 3 measures, and health care institutions planning for future 4 surges. Throughout the COVID-19 pandemic, indicators such 5 as reported cases and percent of PCR tests positive for SARS-6 CoV-2 have been used to guide pandemic response (1-4). Cur-7 rently, the Center for Disease Control and Prevention (CDC)'s 8 Community Levels designate areas as low, medium, or high 9 risk based on reported cases, new COVID-19 hospital admis-10 sions, and percentage of inpatient beds occupied by COVID-19 11 patients (2). 12

13 However, COVID-19 risk metrics have had several weaknesses. First, policymakers have struggled to identify leading 14 indicators of key health outcomes. For example, PCR test 15 positivity was abandoned as a trigger for school closures be-16 cause it did not reliably predict in-school transmission (5). 17 Community metrics have focused on predicting severe disease 18 and mortality (2, 6). For example, the indicators used in CDC 19 Community Levels were selected because they correlated with 20 ICU rates and mortality 3 weeks in the future (2). However, 21

the thresholds for low, medium, and high did not correspond to specific future mortality rates (7), thus complicating the understanding of a "high risk" designation.

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Second, many metrics fail to distinguish different error types. Falsely classifying an area as high risk may prompt unnecessary or harmful interventions, while a false negative may fail to activate needed public health measures (8). Individuals and policymakers may vary in their preferences for avoiding these two types of errors, but current methods fail even to make these preferences explicit (9).

Finally, changes in available data, COVID-19 variants, and levels of immunity can render metrics obsolete as the pandemic evolves (10). For instance, with the omicron variant, cases and hospital admissions have corresponded to lower levels of mortality than in earlier waves. Shifts from PCR to at-home testing and changes in case reporting have also made case data less reliable and available over time (11, 12). Ad hoc updates to risk designations are insufficient to ensure that the metrics remain relevant. Moreover, transparency in the process is key to alleviating concerns about "moving the goalposts" (13).

This paper makes two contributions to address these weaknesses in the context of COVID-19 community risk metrics. First, we propose a framework for predictive accuracy that incorporates preferences over false negatives versus false positives, using weights to optimize the metrics for specific policy objectives. Second, we present a novel method to update risk 42

# Significance Statement

In the rapidly-evolving COVID-19 pandemic, public health risk metrics often become less relevant over time. Risk metrics are designed to predict future severe disease and mortality based on currently-available surveillance data, such as cases and hospitalizations. However, the relationship between cases, hospitalizations, and mortality has varied considerably over the course of the pandemic, in the context of new variants and shifts in vaccine- and infection-induced immunity. We propose an adaptive approach that regularly updates metrics based on the relationship between surveillance inputs and future outcomes of policy interest. Our method captures changing pandemic dynamics, requires only hospitalization input data, and outperforms static risk metrics in predicting high-risk states and counties.

A.M.B designed research and analyzed data; A.M.B., J.A.S., and L.A.H. interpreted results and wrote the paper.

The authors declare no competing interests.

<sup>1</sup>To whom correspondence should be addressed. E-mail: alyssa\_bilinski@brown.edu

thresholds over time and show that this adaptive approach outperforms static metrics. With our approach, we demonstrate that metrics using only new hospital admissions perform as well in prediction as metrics that also include cases and

<sup>52</sup> inpatient bed usage.

#### 53 Materials and Methods

The CDC used indicators available nationwide (cases, hospitalizations, and occupancy of staffed inpatient beds) to develop Community Levels (2). In this research, we used the same indicators to define alternative state and county metrics, then compared these metrics based on ability to predict future health outcomes.

**Outcomes.** The primary evaluation criterion was predictive 60 power for high mortality. We defined "high mortality" as 61  $>\!\!1$  death per 100,000 per week and "very high mortality" as 62 >2 deaths per 100,000 per week. The lower threshold was 63 defined in reference to peak mortality of other respiratory 64 viruses (influenza and respiratory syncytial virus) during a 65 severe season (7, 14). Let  $T_M \in 1, 2$  denote these mortality 66 thresholds. The true outcome was a binary variable equal 67 to 1 if mortality three weeks from the current week (i.e., at 68 time w + 3 in location *i* exceeded the threshold; formally, 69  $Y_{i,w+3} = \mathbb{I}(\text{mortality at } w + 3 > T_M) \in 0, 1.$  In secondary 70 analyses, we evaluated predictive power for ICU admissions, 71 for which we defined "high" as >2 prevalent ICU admissions 72 per 100,000 population per week. 73

We used a 3-week prediction window because previous CDC 74 analyses indicated that this maximized the correlation between 75 indicators and outcomes (2). This also reflects the necessary 76 lead-time for interventions to have an impact on severe out-77 comes; a metric that predicts severe mortality tomorrow will 78 come too late for effective action. We used binary outcomes to 79 80 mirror CDC risk categories and to reflect the common practice of adopting pandemic response interventions in response to 81 threshold crossing. 82

Indicators. Indicators are the observed quantities that enter 83 our prediction models. We used the same three indicators 84 as the CDC's Community Levels: new COVID-19 cases per 85 100,000 (weekly total), new COVID-19 hospital admissions per 86 100,000 (weekly total), and the occupancy of staffed inpatient 87 hospital beds by COVID-19 patients (7-day average). Let 88  $X_{C,i,w}, X_{H,i,w}$ , and  $X_{O,i,w}$  denote the levels of these three 89 indicators respectively, in location i during week w. In our risk 90 prediction models, we used these indicators in 5 combinations: 91 1) new cases only (C), 2) new hospital admissions only (H), 92 3) cases and hospital admissions (CH), 4) hospital admissions 93 and bed occupancy (HO) and 5) all three indicators (CHO). 94

Data. We obtained data on indicators and outcomes at both 95 state and county levels and conducted separate analyses for 96 97 each geographic level. For cases and deaths, we used aggregated counts compiled by state and local health agencies (15). 98 For new COVID-19 admissions and bed occupancy, we used 99 data reported to the U.S. Department of Health and Human 100 Services Unified Hospital Data Surveillance System (16, 17). 101 Consistent with CDC Community Level calculations, we cal-102 culated county-level hospitalizations at the Health Service 103 Area-level to account for care-seeking across counties and com-104 puted measures at the midpoint of each week (2). (HSAs were 105

#### **PRE-PRINT (DRAFT)**

defined by the National Center for Health Statistics to be one or more contiguous counties with self-contained hospital care (18).) In sensitivity analyses, we also present analyses with all inputs and outcomes calculated at the HSA-level.

**Metrics.** Metrics take indicators as inputs and produce a binary 110 high risk classification for a geographic area as output. Our 111 metrics used data available at week w to predict mortality 112 above the pre-specified threshold for mortality,  $T_M$  three weeks 113 in the future and then classify a locality as high risk,  $\hat{Y}_{w+3} = 1$ , 114 or not high-risk  $\hat{Y}_{w+3} = 0$ . (For readability, we omit location 115 subscripts i when referring to a single observation in this 116 section.) 117

**Objective.** We used weighted classification accuracy to compare118metrics on their ability to predict future high mortality, where119the weights reflect preferences for avoiding different types of120errors.121

We assumed a simple underlying decision-analytic frame-122 work: a decision maker receives a prediction of mortality three 123 weeks hence,  $\hat{Y}_{w+3}$ , and takes action in response to that pre-124 diction. If the metric predicts high mortality  $(\hat{Y}_{w+3} = 1)$ , 125 she will take one action; if the model does not predict high 126 mortality  $(\hat{Y}_{w+3} = 0)$ , she will take a different action. Each 127 action has benefits and costs that depend on the true outcome. 128 For example, a true negative conserves public health resources, 129 while a false negative may have costs such as failing to prevent 130 a hospital from becoming overburdened. By contrast, a false 131 positive may have costs such as wasted resources and harming 132 public trust due to unnecessary policy actions. 133

We consider costs in terms of disease burden and public 134 health resources. We anchor costs at 0 in the scenario in which 135 the model correctly predicts low mortality  $(\hat{Y}_{w+3} = Y_{w+3} = 0)$ . 136 If the model incorrectly predicts high mortality  $(\hat{Y}_{w+3} = 1)$ , 137  $Y_{w+3} = 0$ , we denote costs  $R_0$ , of public health resources 138 spent and social costs. By contrast, if a model incorrectly 139 predicts low mortality ( $\hat{Y}_{w+3} = 0, Y_{w+3} = 1$ ), policymakers 140 incur a cost of D, of disease. Last, if a model correctly predicts 141 high mortality  $(\hat{Y}_{w+3} = Y_{w+3} = 1)$ , we assume policymakers 142 implement an intervention that reduces disease by a factor of 143  $\alpha$ , but pay resource costs, for a total cost of  $(1 - \alpha)D + R_1$ . 144

The total cost associated with a particular metric (omitting subscripts for parsimony) is:

$$C(M) = Pr(\hat{Y} = 1, Y = 0)R_0 + Pr(\hat{Y} = 0, Y = 1)D + Pr(\hat{Y} = 1, Y = 1)((1 - \alpha)D + R_1) = Pr(\hat{Y} = 1, Y = 0)R_0 + Pr(\hat{Y} = 0, Y = 1)(\alpha D - R_1) + Pr(Y = 1)((1 - \alpha)D + R_1)$$

Because the last term is constant across all metrics (which cannot affect prevalence of high risk states), this cost is proportional to the weighted misclassification rate:

$$C(M) \propto p_{FP}R_0 + p_{FN}(\alpha D - R_1)$$
$$\propto p_{FP} + p_{FN}wt$$

We can therefore rank metrics based only on performance (i.e., 145 their probabilities of making each error type) and the decision 146 maker's relative preference for false positives compared to 147 false negatives (wt). As the above expression indicates, we can 148

<sup>149</sup> conceptualize weight wt as the ratio of the net benefit from <sup>150</sup> taking action on a true positive  $(\alpha D - R_1)$  to costs incurred <sup>151</sup> by unnecessary action in the case of a false positive  $(R_0)$ .

In our primary analyses, we considered three values of this weight: "neutral" weighted false negatives and false positives equally (wt = 1, equivalent to unweighted accuracy), "don't try wolf" down-weighted false negatives as half the cost of false positives (wt = 0.5), and "better safe than sorry" downweighted false positives as half the cost of false negatives (wt = 2).

We estimated the weighted accuracy rate for each metric as 1 minus the weighted misclassification rate:

$$\delta_{wt}(M) = 1 - p_{FP}w_P - p_{FN}w_N$$

While any  $w_N$  and  $w_P$  such that  $\frac{w_P}{w_N} = wt$  would produce the 159 same ranking of metrics, the absolute value of  $\delta_{wt}$  depends 160 on these  $w_N$  and  $w_P$ , which compare the cost of errors to the 161 benefits of a correct classification. We set  $w_N$  and  $w_P$  such that 162 both error weights are shifted equally in magnitude to achieve 163 the desired ratio, with an increase in one and corresponding 164 decrease in the other. That is, we set  $w_N$  and  $w_P$  using the 165 value a such that  $w_N/w_P = (1-a)/(1+a) = wt$ . With neutral 166 weighting,  $w_N = w_P = 1$ . 167

We used weighted accuracy as our primary measure of performance, with higher weighted accuracy indicating better performance. We further weighted  $\delta_{wt}$  by population to reflect the total proportion of individuals living in a location with an accurate classification (SI Text A).

Static metrics. We considered two types of metrics, static and 173 adaptive. Static metrics used the same procedure in each 174 period to classify a locality as high risk. They differed in 175 their input indicators (the sets C, H, CH, HO, and CHO 176 described above) and the corresponding thresholds used to 177 classify a locality as high risk. We varied the threshold on 178 cases from 0 to 300 per 100,000 (in increments of 50), on 179 new hospitalizations from 0 to 25 per 100,000 (in increments 180 of 5), and on occupancy from 0 to 20% (in increments of 181 5). In what follows, let  $T_C \in [0, 300], T_H \in [0, 25]$ , and 182  $T_O \in [0, 20]$  denote the thresholds for cases, hospitalizations, 183 and occupancy, respectively. We designated the area as high 184 risk if all the indicators in a given indicator set are above their 185 specified thresholds. 186

We also replicated the CDC's Community Levels, designating an area as high-risk if

$$[X_{C,i,w} < 200 \text{ AND } (X_{H,i,w} \ge 20 \text{ OR } X_{O,i,w} \ge 15\%)] \text{ OR}$$
  
 $[X_{C,i,w} \ge 200 \text{ AND } (X_{H,i,w} \ge 10 \text{ OR } X_{O,i,w} \ge 10\%)]$ 

Last, we considered a metric (Z) that designates an area as "high risk" if the outcome is currently above the threshold of interest, i.e.  $\hat{Y}_{i,w+3} = \mathbb{I}(Y_{i,w} = 1)$ .

Adaptive metrics. Adaptive metrics changed thresholds over time 190 based on their ability to predict mortality during the recent 191 past (Figure 1). At time w, we used as training data recent 192 weeks of past indicator data with complete information on 193 outcomes 3 weeks in the future. To these training data, we fit 194 logistic regression models with outcomes on the left-hand side 195 and indicators from three weeks previous on the right-hand 196 side. For example, in the model corresponding to the CHO 197

indicator set, we fit

$$logit(Pr(Y_{i,v} = 1)) = \beta_0 + \beta_1 X_{C,i,v-3} + \beta_2 X_{H,i,v-3} + \beta_3 X_{O,i,v-3}$$
[1] 199

**PRE-PRINT (DRAFT)** 

for  $v \in [w-3, w]$ . From this model, we obtained  $\hat{\beta}_0$ ,  $\hat{\beta}_1$ ,  $\hat{\beta}_2$ , 200 and  $\hat{\beta}_3$ , which we then used to produce fitted probabilities for each locality's mortality three weeks ahead using: 202

$$\widehat{Pr}(Y_{i,w+3}=1) = \operatorname{logit}^{-1} \left(\beta_0 + \beta_1 X_{C,i,v-3} + \beta_2 X_{H,i,v-3} + \beta_3 X_{O,i,v-3}\right)$$
[2] 203

Logistic regression smoothed over noise in the small training data and reduced the dimension of multiple indicators by converting to a probability scale.

With predictions on a probability scale, we specified a 207 probability cutoff above which we classified a location as high 208 risk. We selected this cutoff based on the relative weighting 209 of different error types (wt). We classified a locality as high 210 risk whenever the probability was above 1/(1 + wt) (see SI 211 Text B for optimal cutoff derivation). For our three weights 212 (neutral, don't cry wolf, and better safe than sorry), the cutoff 213 values were  $\frac{1}{2}$ ,  $\frac{2}{3}$ , and  $\frac{1}{3}$ , respectively. With a single predictor, 214 this process would be equivalent to identifying the optimal 215 threshold for the indicator over the training period, accounting 216 for user preferences. 217

We specified analogous models based on CHOZ and HZ indicator sets to assess sensitivity to different functional forms. We also included a simplified version that was updated less frequently, only re-fitting to the training data each quarter, rather than each week. We varied the number of training weeks from 3 to 12 (i.e., fitting Eq. 1 to training data sets as large as  $v \in [w - 11, w]$ ).

Head-to-head comparison. We compared the performance of 225 the metrics during a training period. To define the training 226 period, we began with the period the CDC used to fit Com-227 munity Levels (March 1, 2021 through January 24, 2022). We 228 further allowed the month of March for model fitting and 229 including 3 weeks of future mortality data. Thus, our training 230 period covered April 1, 2021 through December 31, 2021, that 231 is, 2021 Q3 and Q4, with outcomes extending through January 232 21, 2022. 233

We compared performance across metrics separately for 234 each outcome (> 1 or > 2 deaths/100k/week and >2 ICU 235 admissions/100k/week), preference weight (wt = 0.5, 1, or 2), 236 and geographic area (state or county). Within each combi-237 nation of these, we chose the best-performing static metric 238 during the training period from among the 7, 6, 42, 24, or 239 168 possibilities within the C, H, CH, HO, and CHO indicator 240 sets and for adaptive metrics, we selected the best perform-241 ing number of training weeks. The CDC Community Levels 242 and current outcome (Z) metrics were fixed, so there was no 243 selection within this metric type. 244

Performance evaluation. We present weighted accuracy of each 245 selected metric in the training quarters (during which the 246 best performer of each type was selected) and a test period 247 of January 1, 2022 through September 30, 2022 (i.e., 2022 248 Q1-Q3). As a sensitivity analysis, we used December 15, 2021 249 through February 15, 2022 as a training period, to include 250 only omicron-specific training data, and data from February 251 16 through September 20, 2022 as test data. 252

In addition to presenting overall weighted accuracy, we summarize variation in performance across quarters with maximum

198

204

205

206

### **PRE-PRINT** (DRAFT)



**Fig. 1.** Adaptive metrics. We used input data from time w to predict mortality at time w + 3. The diagram shows the model-fitting process using 4 weeks of training data. We trained a model using the 4 most recent weeks with complete outcome data, including inputs from w - 6 to w - 3 and outputs from w - 3 to w. We then used this model, with input data from w, to estimate the probability of "high" or "very high" future mortality at w + 3 and designated a binary prediction based on whether this probability exceeded the user's cutoff. (When a single indicator is used as the only input, this process is equivalent to identifying the optimal threshold for the indicator over the training period, accounting for user preferences.)

quarterly regret, the difference between a metric's predictive accuracy and the best performing metric (19). We calculate regret for each selected metric in each quarter and take the maximum across quarters:

$$MR_M = \max_{q \in \mathcal{Q}} \left( \max_{m \in \mathcal{M}} \delta_{wt,q}(m) \right) - \delta_{wt,q}(M)$$

where M is a metric of interest, Q is a set of quarters,  $\mathcal{M}$  is a set of metrics, and  $\delta_{wt,q}$  is weighted accuracy during quarter q.

Last, to decompose variation between metrics into differences in predictive power and differences in error preferences, we computed sensitivity  $(Pr(\hat{Y}_{i,w+3} = 1|Y_{i,w+3} = 1))$  and specificity  $(Pr(\hat{Y}_{i,w+3} = 0|Y_{i,w+3} = 0))$  across different wtvalues for adaptive metrics and compared these to sensitivity and specificity for static metrics.

262 Simulations. To generalize our approach beyond the specific
263 pandemic periods considered, we developed simple simulations,
264 varying the change in relationship between indicators and
265 outcomes over time and indicator distribution/prevalence of
266 "high" outcomes (SI Text C). We then estimated predictive
267 accuracy across different scenarios.

#### 268 Results

Indicator levels and lagged mortality varied substantially over 269 the course of the study period (Figure 2), which included two 270 major waves of high mortality (delta and omicron BA.1) and 271 a smaller wave in summer 2022 (omicron BA.5) (See Figures 272 S2-S3 for detailed dynamics of indicators by outcome over the 273 study period.) The percentage of population-weighted state-274 275 weeks with high lagged mortality ranged from 94% during Q4 2021 to a low of 17% during Q2 2021. For very high mortality, 276 this ranged from 61% (Q1 2022) to 3% (Q2 2022). We ob-277 served similar variation in counties, with less extreme swings 278 (e.g. from 25% to 75% for high mortality). The relationship 279 between indicators and outcomes shifted substantially over 280 the period studied. In particular, in the third quarter of 2022, 281 cases, hospitalizations, and bed occupancy all increased, but 282 mortality remained lower than in previous waves (Figure 2). 283

Static metrics. In Figure 3, we present the performance of the 284 best-performing static metrics from different indicator sets (C, 285 H, CH, HO, and CHO) during the training and test periods. 286 During the training period, there were only minor differences in 287 training accuracy between metrics that used different indicator 288 sets (e.g., 83-87% in predicting high mortality for states with 289 neutral weighting, 73%-75% for counties). However, for nearly 290 all static metrics and outcomes, test accuracy was lower and 291 more variable than training accuracy (e.g., 45-68% and 54-72% 292 for high mortality in states and counties respectively). 293

Some of this variation is due to the shifting relationship 294 between indicators and lagged outcomes over time. We illus-295 trate this in Figure 4, where gray lines show the performance 296 of metrics based on different hospitalization cutoffs. No single 297 cutoff dominated during the full study period. For example, 298 the cutoff of 5 per 100,000 performed best for high mortality 299 during the first 3 quarters of the study period, with accuracy 300 above 90% in states and 74% in counties, but was the worst 30 performing in Q2-Q3 2022, with less than 50% accuracy. The 302 accuracy of the single best-performing metric also varied across 303 quarters (e.g., from 68-81% for high mortality and 79-91% for 304 very high mortality in counties). 305

Other static metrics similarly reflected the evolving rela-306 tionship between indicators and mortality. While prediction 307 based on current outcome (Z) was the second-worst performing 308 static indicator during the training period (after Community 309 Levels), it performed best during the test period, when waves 310 of infection were less extreme and variable. CDC Community 311 Levels performed relatively worse compared to other static 312 metrics at predicting high mortality during the training period, 313 but similar or better during the test period; the converse was 314 true for predicting very high mortality (Figure 3). Overall, 315 metrics that used hospitalizations and bed occupancy per-316 formed most consistently across training and test periods, but 317 we would have been unable to discern this with only train-318 ing data. Across static metrics, training accuracy was an 319 unreliable signal of test accuracy. 320

Adaptive metrics.Adaptive metrics consistently outperformed321static metrics for both outcomes in training and test periods322(Figure 3).For example, when predicting high mortality in323

# PRE-PRINT (DRAFT)



Fig. 2. State-level lagged mortality vs. indicator levels by quarter. Columns indicate different indicators (weekly cases per 100,000 population, new hospital admissions per 100,000, and percentage of inpatient beds occupied by COVID-19 patients), and rows indicate quarters. The x-axis displays indicator values on a log scale and y-axis displays 3-week ahead mortality per 100,000 population on a log scale. Each point on the scatterplot is a state-week. Colors show mortality outcome level. The vertical gray dotted lines indicate thresholds from CDC Community Levels for each indicator ( $\geq 200$  cases/100K/week and  $\geq 10$  new admissions/100K/week or  $\geq 10\%$  COVID-19 bed occupancy.) See Figure S1 for a county-level plot.

# **PRE-PRINT** (DRAFT)



#### States

#### Counties

	Neutral				Don't cry wolf (0.5x FN)				Better safe than sorry (0.5x FP)				
	Training	Training MR	Test	Test MR	Training	Training MR	Test	Test MR	Training	Training MR	Test	Test MR	_
Adaptive: CHOZ Adaptive: CHO Adaptive: HZ Simplified adaptive: HZ Community Levels CHO HO CH HO CH H C Prevalence	77 76 76 75 67 73 74 74 74 74 75 74 75 59	0 2 4 4 19 6 7 7 3 8 4 36	75 73 75 74 69 72 70 70 57 56 54 45	0 3 1 4 9 4 9 9 31 31 33 51	79 78 78 76 76 74 78 78 78 78 78 77 77 59	0 3 2 5 7 14 3 3 2 3 4 4 42	80 80 80 73 71 73 73 68 67 54 45	1 2 2 3 15 12 19 19 27 29 39 39 58	81 79 79 57 73 70 70 70 70 70 70 78 79 79 59	0 4 5 4 36 14 17 17 4 4 3 38	75 70 75 75 65 73 68 68 68 66 66 66 63 45	0 7 0 1 21 6 12 12 12 12 12 12 20 48	>1 death/100K/wk
Adaptive: CHOZ Adaptive: HZ Simplified adaptive: HZ Community Levels CHO HO CH H C CH CH CH	81 79 80 79 80 77 80 80 80 80 80 80 80 35	1 3 3 5 4 5 4 5 4 5 4 71	86 86 86 75 80 83 83 83 82 82 65 26	0 1 2 1 6 6 8 9 32 82	84 82 83 83 82 78 83 83 83 83 83 83 83 83 83 83 83 83 83	0 4 1 3 12 1 2 1 3 3 76	88 89 72 78 85 88 84 87 71 26	1 0 2 0 34 16 8 1 11 2 27 85	82 80 81 79 79 79 79 79 80 79 79 35	0 4 3 4 9 8 5 5 4 4 5 69	85 84 85 84 77 81 80 80 74 74 66 26	0 2 1 13 10 11 12 22 23 28 79	>2 deaths/100K/wk

Fig. 3. Head-to-head comparison results. The top plots display results from state-level analyses and the bottom plots display results from county-level analyses, both weighted for population. Metrics are displayed on the left, with training data from Q2-Q4 2021 and test data from Q1-Q3 2022. Cells report weighted accuracy and maximum regret (MR) over training and test periods. Rows vary outcomes, and columns vary preferences for false positive versus false negatives, with "neutral" corresponding to unweighted accuracy. Prevalence indicates the proportion of high location-weeks in a given time period. A version including HSA-level analyses can be found in Figure S4. Weighted accuracy by quarter, including for intensive care usage, is presented in Figures S5-S7.

# PRE-PRINT (DRAFT)



Fig. 4. Weighted accuracy by metric. The top plot displays states, and the bottom plot displays counties. Columns indicate different outcomes. The x-axis indicates quarter, and the y-axis predictive accuracy (neutral weighting). Grey lines depict metrics based on new hospital admissions exceeding the row threshold. The red line indicates CDC Community Level and the blue line an adaptive metric (HZ). A version with HSA-level results can be found in Figure S8.

states with neutral weighting, adaptive metrics had overall ac-324 curacy of 86-89% in the training period and 80-83% in the test 325 period; for very high mortality, this was 87-90% and 92-94% re-326 spectively. While all adaptive functional forms performed well, 327 328 metrics corresponding to CHOZ and HZ slightly outperformed 329 CHO and the simplified version with less frequent updating. Importantly, while adaptive metrics performed similarly to 330 static metrics during some quarters, they rarely underper-331 formed by a substantial margin and often achieved substantial 332 gains (Figure 4). This was reflected in regret, which was mini-333 mized by CHOZ and HZ adaptive metrics for both outcomes. 334 CHOZ and HZ adaptive metrics also weakly dominated static 335 indicator-based metrics and Community Levels in the sense 336 that they could achieve at least equal (and often higher) sen-337 sitivity and specificity for at least one value of wt (Figure 338 S9). 339

Alternative preferences, secondary outcomes, and sensitivity 340 analyses. Adaptive metrics similarly outperformed static met-341 rics for across preference weights (Figure 3) and for a secondary 342 outcome of ICU bed usage over 2 per 100,000 (Figure 4). The 343 gain in weighted accuracy for adaptive metrics was higher 344 when estimated at the HSA level rather than at the county 345 level (about 2 percentage points for both mortality outcomes 346 with neutral weighting). Running the training period from De-347 cember 15 to February 15 to capture the omicron variant did 348 not substantially alter the relative benefit of adaptive metrics, 349 with a 14 percentage point increase in weighted accuracy in 350 351 states for high mortality compared to Community Levels with a neutral weighting (compared to 11% in the base case) and 352 7% in counties (compared to 6%). 353

Simulations. In simulations, adaptive methods outperformed 354 static methods when the relationship between indicators and 355 outcomes was changing over time, regardless of whether out-356 come prevalence was constant or wave-driven. There was no 357 gain when the relationship between indicators and outcomes 358 was static; adaptive metrics performed worse than static met-359 rics when indicator prevalence was highly variable, and there 360 could be insufficient training data near the threshold to esti-361 mate the optimal cutoff. 362

#### Discussion 363

We proposed an adaptive approach to estimating local risk 364 which continually updates metrics to ensure they predict out-365 comes of policy interest. We showed that this would have 366 367 outperformed static approaches, including CDC Community Levels over the past year. Our metrics have a unique advan-368 tage in a rapidly evolving pandemic context. They quickly 369 pick up new information as the relationship between indicators 370 and lagged mortality shifts, allowing us refine the threshold 371 for "high risk" and improve discrimination. 372

Previous papers have proposed adaptive policies for COVID-373 374 19 management, in which policymakers shift responses depending on observed indicators like cases and deaths (20-22). We 375 extend this work by allowing the trigger thresholds for indi-376 cators to also vary over time. Such an approach could be 377 particularly advantageous for maintaining public trust when 378 the relationship between indicators and outcomes is not vet 379 well-understood or is changing over time (23). 380

Our approach draws on ideas that have been applied in 38 the online calibration literature and in forecasting, but have 382

## PRE-PRINT (DRAFT)

not vet been widely applied for population risk metrics (6, 24 383 26). In contrast to some other applications, we particularly 384 emphasize parsimony for policy metrics, demonstrating that 385 policymakers can obtain equal predictive performance with 386 fewer input indicators, potentially reducing the burden of 387 data collection on state and local public health departments. 388 Similar to other authors, we find hospitalizations to be a 389 particularly powerful predictor of future mortality (6). We 390 further emphasize that it is valuable to collect real-time data 391 on outcomes of policy interest, like mortality. (In the case of 392 COVID-19, while state mortality is still collected and reported 393 weekly, many counties have reduced reporting frequency (15).) 394

Our method can also reflect a policymaker's preferences 395 for the trade-off between avoiding false negative and false 396 positives, filling a previously-identified gap between models 397 and decision theory (27). In practice, different indicators could 398 be used to guide different policies. For the most burdensome 399 policies (e.g., business closures), policymakers might prefer a 400 low risk of false negatives, while less burdensome policies (e.g., 401 distribution of rapid tests) might have a higher tolerance for 402 false positives. 403

There are several limitations to this study. First, we model 404 only outcomes related to severe disease and death from COVID-405 19, as national policymakers have designated these priority 406 outcomes. Nevertheless, metrics to track illness are also impor-407 tant for understanding the full burden of COVID-19, which can 408 also include disruptions from illness as well as Long COVID, 409 as is work to predict surges with longer lead time (26, 28). 410 In addition, no adaptive framework can automatically incor-411 porate all possible variation. Manual tuning may be needed, 412 for example, if the frequency of reporting of hospitalization 413 changes over time. Furthermore, in high-risk situations, such 414 as an unusually lethal new variant identified in one country, it 415 may be preferable to implement preventative measures even 416 prior to observing a changing relationship between indicators 417 and severe outcomes. More broadly, metrics could be refined 418 to upweight performance during critical periods such as the 419 start of a surge or consider dynamic decision-making. Finally, 420 future work could also expand these results to other contexts, 421 such as prediction of combined respiratory disease outcomes 422 (including influenza and RSV) and consider other models for 423 risk prediction. Overall, adaptive metrics may be a powerful 424 tool for designing trustworthy, transparent metrics to guide 425 infectious disease policy. 426

#### References.

- 1. CDC, COVID Data Tracker (https://covid.cdc.gov/covid-data-tracker) (2020).
- 2. CDC, Science Brief: Indicators for Monitoring COVID-19 Community Levels and Making Public Health Recommendations (https://www.cdc.gov/coronavirus/2019-ncov/science/ science-briefs/indicators-monitoring-community-levels.html) (2022).

427

428

429

430

431

432

433

434

435

436

437

438

439

442

443

444

445

447

- 3. A Reinhart, et al., An open repository of real-time COVID-19 indicators. Proc. Natl. Acad. Sci. 118, e2111452118 (2021) Publisher: Proceedings of the National Academy
- School Reopening Thresholds Vary Widely Across the Country (year?) 4 E Shapiro, D Rubinstein, Did It Hit 3%? Why Parents and Teachers Are Fixated on One
- Number, The New York Times (2020),
- SJ Fox, et al., Real-time pandemic surveillance using hospital admissions and mobility data Proc. Natl. Acad. Sci. 119, e2111870119 (2022) Publisher: Proceedings of the National Academy of Sciences
- 7. JA Salomon, A Bilinski, Evaluating the Performance of Centers for Disease Control and 440 Prevention COVID-19 Community Levels as Leading Indicators of COVID-19 Mortality. Annals 441 Intern. Medicine 175, 1240-1249 (2022)
- World Health Organization. Regional Office for the Western Pacific, Calibrating long-term nonpharmaceutical interventions for COVID-19 : principles and facilitation tools, (WHO Regional Office for the Western Pacific), Technical Report WPR/DSE/2020/018 (2020)
- JG Allen, H Jenkins, Opinion | The Hard Covid-19 Questions We're Not Asking. The New York 446 Times (2021).
- JK Varma, Opinion | When Do Masks Come Off? The Hard Truth About Lifting Covid Restric-10. 448 tions. The New York Times (2022). 449

#### **PRE-PRINT** (DRAFT)

- B Rader, Use of At-Home COVID-19 Tests United States, August 23, 2021–March 12, 2022.
   MMWR. Morb. Mortal. Wkly. Rep. 71 (2022).
- D McPhillips, Covid-19 data reporting is becoming less frequent, making trends harder to track
   (2022).
- Opinion | No, the pandemic 'goal posts' aren't being moved. Wash. Post (2022).
   EJ Emanuel, M Osterholm, CR Gounder, A National Strategy for the "New Normal" of Life
- EJ Emanuel, M Osternomi, CA Gounder, A National Strategy for the New Normal of Life With COVID. JAMA 327, 211–212 (2022).
   5. Coronavirus (Covid-19) Data in the United States (https://oithub.com/nvtimes/covid-19-data)
- 457 15. Coronavirus (Covid-19) Data in the United States (https://github.com/nytimes/covid-19-data)
   458 (2022).
- 459 16. COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries
   460 (https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/
   461 g62h-syeh) (2022).
- COVID-19 Reported Patient Impact and Hospital Capacity by Facility (https://healthdata.gov/
   Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/anag-cw7u) (2022).
- 18. DM Makuc, B Haglund, DD Ingram, JC Kleinman, JJ Feldman, Health service areas for the
- 465 United States. Vital Heal. Stat. Ser. 2, Data Eval. Methods Res. pp. 1–102 (1991).
  466 J. Berger, Statistical Decision Theory: Foundations, Concepts, and Methods. (Springer Science
- & Business Media), (2013) Google-Books-ID: TT\_jBwAAQBAJ.
   R Yaesoubi, et al., Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. *Med. Decis. Mak.* 41,
- 386–392 (2021) Publisher: SAGE Publications Inc STM.
  R Yaesoubi, et al., Simple decision rules to predict local surges in COVID-19 hospitalizations during the winter and spring of 2022. *medRxiv: The Prepr. Serv. for Heal. Sci.* p.
  2021.12.13.21267657 (2021).
- C Castillo-Laborde, et al., Assessment of event-triggered policies of nonpharmaceutical interventions based on epidemiological indicators. J. Math. Biol. 83, 42 (2021).
- 476 23. A Lavazza, M Farina, The Role of Experts in the Covid-19 Pandemic and the Limits of Their
   477 Epistemic Authority in Democracy. *Front. Public Heal.* 8 (2020).
- DJ McDonald, et al., Can auxiliary indicators improve COVID-19 forecasting and hotspot prediction? *Proc. Natl. Acad. Sci.* 118, e2111453118 (2021) Publisher: Proceedings of the National Academy of Sciences.
- EL Ray, et al., Comparing trained and untrained probabilistic ensemble forecasts of COVID-19
   cases and deaths in the United States. Int. J. Forecast. (2022).
- LM Stolerman, et al., Using digital traces to build prospective and real-time county-level early
   warning systems to anticipate COVID-19 outbreaks in the United States. *Sci. Adv.* 9, eabq0199
   (2023) Publisher: American Association for the Advancement of Science.
- L Berger, et al., Rational policymaking during a pandemic. Proc. Natl. Acad. Sci. 118, e2012704118 (2021) Publisher: Proceedings of the National Academy of Sciences.
- NE Kogan, et al., An early warning approach to monitor COVID-19 activity with multiple digital traces in near real time. *Sci. Adv.* 7, eabd6989 (2021) Publisher: American Association for the Advancement of Science.

491 Data Archival. Data and code will be made publicly available
 492 on GitHub.

ACKNOWLEDGMENTS. The authors were supported by the
 Centers for Disease Control and Prevention though the Council of

State and Territorial Epidemiologists (NU38OT000297-02; AB, JAS)

and the National Institute on Drug Abuse (3R37DA01561217S1;

<sup>497</sup> JAS). Funders had no role in the design and conduct of the study; <sup>498</sup> collection, management, analysis, and interpretation of the data;

preparation, review, or approval of the manuscript; and decision to
 submit the manuscript for publication.